The Charles Stark Draper Laboratory Inc. has inked a three year partnership with Pfizer to create personalised versions of Draper’s Microphysiological Systems (MPS), for cheaper and more effective preclinical testing.
Proteomics International has agreed to collaborate with inVentiv Health to develop biosimilars and biologics, which will begin with structural and functional characterization.
Evotec says it is confident underlying growth, expansion of its clinical stage pipeline and upcoming milestone payments will counter Q1’s downcast results.
Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...
Outsourcing-Pharma presents its weekly round-up of the latest chops and changes within the pharmaceutical jobs market, with news from Patheon, AmerisourceBergen and Premier Research.
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
InhibOx and the Cambridge Crystallographic Data Centre (CCDC) say new drug discovery services partnership is motivated by market need for CADD expertise.
TTP LabTech has launched a contract screening service to assist various aspects of clients’ drug development programmes, from target identification through to preclinical toxicology.
Artel has introduced a new feature for its Multichannel
Verification System (MVS), which includes an automation function
that allows for time savings and reducing human error.
According to a recent report, the global bioinformatics market is
currently estimated at about $1.4 billion (€1.1 billion). It is
expected to grow at an average annual growth rate of 15.8 per cent
to reach nearly $3 billion by 2010,...
The pharmaceutical industry must cut the time its drugs linger in
development and terminate less promising projects earlier if it is
to improve the efficiency and productivity of its R&D
programmes.
